The Shaken Baby Syndrome Myth
life-threatening and legally shattering medical misdiagnosis

* SBS: To date, an unproven medical hypothesis without supporting scientific evidence, depriving live infants of proper diagnosis and treatment, and caretakers of justice   * The diagnostic triad: symptoms aren't caused by shaking   *Accidental and medical causes of the same symptoms: short falls, accidental injury, hypoxia (oxygen deprivation) infection (encephalitis, etc.), metabolic diseases and other medical conditions, vaccine injury, birth injuries  *Head impact: false criteria for amount of force required  * the JOHN LAVERTY--BABY CASEY FAMILY TRAGEDY
HOME:  http://legaljustice4john.com

Thrombocytopenia:
vaccinations, drugs, or disease-caused
Abnormal bleeding, bruising, subdural hematomas, retinal hemorrhages
(symptoms falsely attributed exclusively to Shaken Baby Syndrome)

" Generally speaking, in humans, a normal platelet count ranges from 150,000 and 450,000 per mm3 (microlitre).[1] These limits, however, are determined by the 2.5th lower and upper percentile, and a deviation does not necessarily imply any form of disease. The number of platelets in a blood sample also decreases rather quickly with time and a low platelet count may be caused by a delay between sampling and analysis." --Wikipedia

Photos of a condition associated with vaccinations, drugs, and original disease from unknown causes, resulting in abnormal bruising, hemorrhagic conditions, retinal hemorrhage, subdural hematoma, bleeding in the brain (symptoms associated with SBS cases, whose "experts" falsely claim are exclusive to "shaken babies")

Online pictures of thrombocytopenia
from different medical websites

 

 

 


 

Thrombocytopenia: Retinal Hemorrhages

Photos of a condition associated with vaccinations, drugs, and original disease from unknown causes, resulting in abnormal bruising,
hemorrhagic conditions, retinal hemorrhage, subdural hematoma, bleeding in the brain

Types of retinal hemorrhages

http://www.google.com/search?q=thrombocytopenia+%2B+retinal+hemorrhage (37,100 hits)

Massive bilateral vitreoretinal hemorrhage in patient with chronic ...
thrombocytopenia [4]. The retinal hemorrhages were generally flame-shaped, but were occasionally
either subhyaloid or had broken through the internal ...
www.springerlink.com/index/WU362673512801QW.pdf


Vaccine-induced THROMBOCYTOPENIA journal articles (a small sample from http://scholar.google.com)

  • THROMBOCYTOPENIA AFTER IMMUNIZATION WITH MEASLES VACCINES:
    REVIEW OF THE VACCINE ADVERSE EVENTS REPORTING SYSTEM (1990 TO 1994). Brief Report
    Pediatric Infectious Disease Journal. 15(1):88-90, January 1996.
    Beeler, Judy M.D.; Varricchio, Frederick M.D.; Wise, Robert M.D., M.P.H.
  • An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system - all 4 versions »
    JA Singleton, JC Lloyd, GT Mootrey, ME Salive, RT … - Vaccine, 1999 - Elsevier
    ... Update: vaccine side effects, adverse reactions, contraindications ... and R. Wise,
    Thrombocytopenia after immunization with ... of the vaccine adverse events reporting ...
  • Postmarketing Surveillance and Adverse Drug Reactions Current Perspectives and Future Needs - all 4 versions »
    T Brewer, GA Colditz - JAMA, 1999 - Am Med Assoc
    ... vaccination and febrile convulsions or idiopathic thrombocytopenia purpura after ...
    data have been used to describe previously unreported vaccine adverse effects. ...
  • Clin Exp Rheumatol. 2004 Nov-Dec;22(6):749-55.Links
    A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins
    following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System
    (VAERS) database and literature review.
    Geier MR, Geier DA.

    The Genetic Centers of America, MedCon, Inc., Silver Spring, Maryland 20905, USA. mgeier@comcast.net

  • OBJECTIVES: Adverse events and positive re-challenge of symptoms reported in the scientific literature and to the Vaccine Adverse Event Reporting System (VAERS) following hepatitis B vaccination (HBV) were examined. METHODS: The VAERS and PubMed (1966-2003) were searched for autoimmune conditions including arthritis, rheumatoid arthritis, myelitis, optic neuritis, multiple sclerosis (MS), Guillain Barré Syndrome (GBS), glomerulonephritis, pancytopenia/thrombocytopenia, fatigue, and chronic fatigue, and Systemic Lupus Erythematous (SLE) following HBV. RESULTS: HBV was associated with a number of serious conditions and positive re-challenge or significant exacerbation of symptoms following immunization. There were 415 arthritis, 166 rheumatoid arthritis, 130 myelitis, 4 SLE, 100 optic neuritis, 101 GBS, 29 glomerulonephritis, 283 pancytopenia/thrombocytopenia, and 183 MS events reportedfollowing HBV A total of 465 positive re-challenge adverse events were observed following adult HBV that occurred sooner and with more severity than initial adverse event reports. A case-report of arthritis occurring in identical twins was also identified. CONCLUSIONS: Evidence from biological plausibility, case-reports, case-series, epidemiological, and now for positive re-challenge and exacerbation of symptoms, and events in identical twins was presented. One would have to consider that there is causal relationship between HBV and serious autoimmune disorders among certain susceptible vaccine recipients in a defined temporal period following immunization. In immunizing adults, the patient, with the help of their physician, should make an informed consent decision as to whether to be immunized or not, weighing the small risks of the adverse effects of HBV with the risk of exposure to deadly hepatitis B virus.

  • 1: N Y State J Med. 1972 Feb 15;72(4):499.Links
    Thrombocytopenia associated with rubella vaccination.
    Bartos HR.

  • PEDIATRICS Vol. 89 No. 2 February 1992, pp. 318-324

    The Ricochet of Magic Bullets: Summary of the Institute of Medicine Report, Adverse Effects of Pertussis and Rubella Vaccines
    Christopher P. Howson PhD1 and Harvey V. Fineberg MD, PhD1

    1 From the Institute of Medicine of the National Academy of Sciences, Washington, DC. Dr Howson is Deputy Director of the Division of International Health of the Institute of Medicine and Dr Fineberg is dean of the Harvard School of Public Health, Boston, MA.

    On July 3, 1991, the National Academy of Sciences' Institute of Medicine (IOM) released a reported entitled, Adverse Effects of Pertussis and Rubella Vaccines,1 in response to a congressional request to review evidence about a set of serious adverse events and immunization with pertussis and rubella vaccines. The request originated in the 1986 National Childhood Vaccine Injury Act (Public Law 99-660), whose primary purpose was to establish a federal compensation scheme for persons potentially injured by a vaccine; Section 312 of Public Law 99-660 called for the IOM review.

    Over the course of its 20-month study, the 11-member interdisciplinary committee constituted by IOM to conduct the review examined altogether 18 adverse events for pertussis vaccine—infantile spasms; hypsarhythmia; aseptic meningitis; acute encephalopathy; chronic neurologic (permanent brain) damage; deaths classified as sudden infant death syndrome (SIDS); anaphylaxis, autism; erythema multiforme or other rashes; Guillain-Barré syndrome (polyneuropathy); peripheral mononeuropathy; hemolytic anemia; juvenile diabetes; learning disabilities and hyperactivity; protracted inconsolable crying or screaming; Reye's syndrome; shock and "unusual shock-like state" with hypotonicity, hyporesponsiveness, and short-lived convulsions (usually febrile); and thrombocytopenia—and 4 adverse events for rubella vaccine—acute arthritis; chronic arthritis; radiculoneuritis and other neuropathies; and thrombocytopenic purpura. In conducting its review, the committee recognized that its charge was to focus on questions of causation and not broader topics, such as cost-benefit or risk-benefit analyses of vaccination.

    This summary begins with a brief history of events leading to the IOM study, then reviews the methods used by the committee to evaluate the evidence, summarizes the committee's conclusions for these adverse events, and offers directions for future investigation of adverse events in connection with widely used health interventions, such as vaccination.
    Submitted on November 5, 1991
    Accepted on November 21, 1991

  • Hepatitis and death following vaccination with 17D-204 yellow fever vaccine - all 3 versions »
    RC Chan, DJ Penney, D Little, IW Carter, JA … - The Lancet, 2001 - Elsevier
    ... to by: Rarity of adverse effects after 17D ... on Jan 31, he developed thrombocytopenia,
    clotting abnormalities ... not support previous yellow fever vaccination in our ...

  • Comment on:
    Lancet. 1994 Nov 5;344(8932):1293.

    Thrombocytopenia reported in association with hepatitis B and A vaccines.
    Meyboom RH, Fucik H, Edwards IR.

 

http://tinyurl.com/4z2za8

Drug-Induced THROMBOCYTOPENIA

http://www.neurology.org/cgi/content/abstract/54/6/1240

Neurologic complications in immune-mediated heparin-induced thrombocytopenia
C. Pohl, MD, U. Harbrecht, MD, A. Greinacher, MD, I. Theuerkauf, MD, R. Biniek, MD, P. Hanfland, MD and T. Klockgether, MD

From the Departments of Neurology (Drs. Pohl and Klockgether), Transfusion Medicine (Drs. Pohl, Harbrecht, and Hanfland) and Pathology (Dr. Theuerkauf), Rheinische Friedrich Wilhelms Universität, Bonn; Institute of Immunology and Transfusion Medicine (Dr. Greinacher), Ernst Moritz Arndt Universität Greifswald; and the Rheinische Landesklinik Bonn (Dr. Biniek), Bonn, Germany.

Address correspondence and reprint requests to Dr. C. Pohl, Department of Neurology, University of Bonn, Sigmund-Freud-Straße, D-53105 Bonn, Germany; e-mail: c.pohl@uni-Bonn.de

OBJECTIVE: To evaluate neurologic complications in patients with immune-mediated heparin-induced thrombocytopenia (HIT) with respect to incidence, clinical characteristics, outcome, and therapy.

METHODS: One hundred and twenty consecutive patients with immune-mediated HIT were recruited over a period of 11 years and studied retrospectively for the occurrence of neurologic complications. Diagnosis of HIT was based on established clinical criteria and confirmed by detection of heparin-induced antibodies using functional and immunologic tests.

RESULTS: Eleven of the 120 patients (9.2%) presented with neurologic complications; 7 suffered from ischemic cerebrovascular events, 3 from cerebral venous thrombosis, and 1 had a transient confusional state during high-dose heparin administration. Primary intracerebral hemorrhage was not observed. The relative mortality was much higher (Chi-square test, p < 0.01) in HIT patients with neurologic complications (55%) as compared to patients without neurologic complications (11%). The mean platelet count nadir in neurologic patients was 38 ± 25 x 109/l on average, and was lower in patients with fatal outcome compared to those who survived (21 ± 13 x 109/l versus 58 ± 21 x 109/l; p < 0.05, Wilcoxon test). In three patients neurologic complications preceded thrombocytopenia. There was a high coincidence of HIT-associated neurologic complications with other HIT-associated arterial or venous thrombotic manifestations.

CONCLUSION: Neurologic complications in HIT are relatively rare, but associated with a high comorbidity and mortality. HIT-associated neurologic complications include cerebrovascular ischemia and cerebral venous thrombosis. They may occur at a normal platelet count

 

http://medicineworld.org/physicians/hematology/thrombocytopenia.html


Figure 2. Computed tomography demonstrating large right frontal intracerebral hemorrhage.

 

Thrombocythemia

The opposite of Thrombocytopenia is Thrombocythaemia (British spelling for Thrombocythemia) which involves
INCREASED platelet counts. Clumping platelets may cause strokes in this condition.

http://tinyurl.com/6dhtz9